Epilepsy
Conditions
Brief summary
Legislation to allow medical marijuana has had a significant impact on the pediatric population of Colorado. There have been many reported different effects and properties of each of the over 60 known cannabinoids found in marijuana. The main exposures in pediatrics have involved the use of Cannabidiol (CBD) high- and Tetrahydrocannibinol (THC) low-content hash oil in children with epilepsy. The reported benefit of this oil is to have the anticonvulsant properties of CBD without the psychoactive components of THC. Human studies on the efficacy of CBD on epilepsy are few and limited. The investigators' specific aims are the following: * Specific Aim 1: Describe the plasma pharmacokinetics of Cannabidiol (CBD), Tetrahydrocannibinol (THC), and their respective metabolites in pediatric patients with epilepsy. * Specific Aim 2: Describe the plasma pharmacokinetics of other antiepileptic drugs (AEDs) taken in conjunction with CBD in order to evaluate drug interactions. * Specific Aim 3: Describe parental perception of efficacy of CBD on control of epilepsy. The investigators will recruit children and their parents who are currently using or plan to use CBD for their seizure disorder. This study will NOT be providing patients with CBD. Consenting subjects will undergo a number of blood and urine collection that will be analyzed to describe the pharmacokinetics and possible drug interactions of CBD in pediatric epilepsy.
Interventions
None listed
Sponsors
University of Colorado, Denver
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
31 Days to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients \> 1 month and \< 18 years of age who use, or plan to use, orally administered CBD rich hash oil for treatment of epilepsy * Parent/legal guardian accompanying patient who is \>= 18 year of age and non-incarcerated.
Exclusion criteria
* Patients without epilepsy/seizure disorder as diagnosed by a neurologist * Have known abnormalities in liver (AST, ALT, INR above normal range), or kidney function (creatinine above normal range) * Patient is known to be pregnant at time of enrollment (however, guardians who may be pregnant can be included for survey completion) * Patient is ward of the state * Unable to provide verification of hash oil potency and content
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Describe the plasma pharmacokinetics of Cannabidiol (CBD), other antiepileptic drugs, Tetrahydrocannibinol (THC), and their respective metabolites in pediatric patients with epilepsy. | Change from baseline to 12 hours post CBD administration | Blood samples will be obtained at 6 time periods: at baseline prior to the first dose of CBD and at the following time intervals after administration of CBD: 1 hour, 2 hour, 4 hour, 8 hour, and 12 hours after administration of CBD. Urine will be collected for first 8 hours to account for renal elimination of CBD and antiepileptics. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demographic Data | collected once at study visit | — |
| Medication History | collected once at study visit | — |
| CBD History | collected once at study visit | — |
| Describe parental perception of efficacy of CBD on control of epilepsy | collected once at study visit | A parental survey will be completed. |
Countries
United States
Outcome results
None listed